NCT01879462View on ClinicalTrials.gov

A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 14, 2013

Primary Completion Date

January 10, 2014

Study Completion Date

January 10, 2014

Conditions
Hepatitis C, Chronic
Interventions
DRUG

GSK2878175

Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.

DRUG

Placebo

Visually matching GSK2878175

Trial Locations (1)

2031

GSK Investigational Site, Randwick

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01879462 - A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects | Biotech Hunter | Biotech Hunter